|
|
|
|
In an episode of The Business of Biotech podcast, Dr. Loretta Itri sat down to explore the promise of TRODELVY®️, a first-in-class ADC for the treatment of triple-negative breast cancer that she helped shepherd from late-stage development to market, and other ADCs as transformative treatments for a range of malignancies and intractable diseases.
|
|
|
|
|
Single-use (SU) systems show significant promise for antibody‑drug conjugate (ADC) manufacturing. However, the use of organic solvents in the ADC process raises concerns about potential leachables from the plastic and elastomeric materials in SU components. To address these questions, extractables studies were conducted on a SU chromatography column housing and two different SU flow paths.
|
|
|
|
|
Watch to learn more about the Return on Invested Capital (ROIC) for an automated facility at Biophorum Digital Plant Maturity Model (DPMM) levels of 2.0, 2.5, and 3.0. Gain a comprehensive understanding of the ROIC benefits of an automated manufacturing facility and its relationship to the digital maturity of your operation.
|
|
|
|
|
Molecular diversity is rapidly increasing for biotherapeutics and monoclonal antibodies (mAbs). To help make the most of these new therapeutic possibilities, both manufacturing and process development technologies need to evolve. Watch to learn how to select the right resin for your antibody variant purification project.
|
|
|
